1-20 of 31
Neil H. Bander
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract CT225: Quantitative assessment of PSMA imaging before and after 177Lu-PSMA-617 treatment in a Ph I/II trial

Jones Trevor Nauseef, Charlene Thomas, Michael Sun, Nicole Jacobs, Andrés Ricaurte Fajardo, Sam Ruder, Escarleth Fernandez, Zachary Davidson, Amie Patel, A. Oliver Sartor, Shankar Vallabhajosula, Ana Molina, Cora N. Sternberg, David M. Nanus, Sandra Huicochea Castellanos, Joseph Osborne, Neil H. Bander, Timothy Perk, Scott Tagawa
Journal: Cancer Research
Cancer Res (2024) 84 (7_Supplement): CT225.
https://doi.org/10.1158/1538-7445.AM2024-CT225
Published: 05 April 2024
View articletitled, Abstract CT225: Quantitative assessment of PSMA imaging before and after 177Lu-PSMA-617 treatment in a Ph I/II trial
Journal Articles

Abstract CT014: Phase I dose-escalation study of fractionated dose 225Ac J591 for metastatic castration resistant prostate cancer

Jones T. Nauseef, Michael Sun, Charlene Thomas, Mahelia Bissassar, Escarleth Fernandez, Zachary Davidson, Amie Patel, Angela Tan, Tessa A. Chamberlain, Kara Earle, Rebecca Wunder, Sabrina Guervil, Sandra H. Castellanos, Judith Stangl-Kremser, Peter S. Gregos, Joseph R. Osborne, Karla V. Ballman, Ana M. Molina, Cora N. Sternberg, David M. Nanus, Neil H. Bander, Scott T. Tagawa
Journal: Cancer Research
Cancer Res (2023) 83 (8_Supplement): CT014.
https://doi.org/10.1158/1538-7445.AM2023-CT014
Published: 14 April 2023
View articletitled, Abstract CT014: Phase I dose-escalation study of fractionated dose 225Ac J591 for metastatic castration resistant prostate cancer
Journal Articles

Abstract CT143: Results of combined targeting of prostate-specific membrane antigen (PSMA) with alpha-radiolabeled antibody 225Ac-J591 and beta-radiolabeled ligand 177Lu-PSMA I&T: preclinical and initial phase 1 clinical data in patients with metastatic castration-resistant prostate cancer (mCRPC)

Scott T. Tagawa, Edward Fung, Muhammad O. Niaz, Mahelia Bissassar, Sharon Singh, Amie Patel, Angela Tan, Juana Martinez Zuloaga, Sandra Huicochea Castellanos, Jones T. Nauseef, Ana Molina, Cora Sternberg, David M. Nanus, Joseph Osborne, Neil H. Bander
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): CT143.
https://doi.org/10.1158/1538-7445.AM2022-CT143
Published: 15 June 2022
View articletitled, Abstract CT143: Results of combined targeting of prostate-specific membrane antigen (PSMA) with alpha-radiolabeled antibody 225Ac-J591 and beta-radiolabeled ligand 177Lu-PSMA I&T: preclinical and initial phase 1 clinical data in patients with metastatic castration-resistant prostate cancer (mCRPC)
Journal Articles

Abstract 1264: CTC-based biomarker analysis and correlation with clinical response to PSMA-TRT in mCRPC

Giuseppe Galletti, Prerna Vatsa, Joseph R. Osborne, Neil H. Bander, David M. Nanus, Scott T. Tagawa, Paraskevi Giannakakou
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 1264.
https://doi.org/10.1158/1538-7445.AM2022-1264
Published: 15 June 2022
View articletitled, Abstract 1264: CTC-based biomarker analysis and correlation with clinical response to PSMA-TRT in mCRPC
Journal Articles

Abstract 6511: Androgen receptor (AR) genomic alterations and clinical outcome with prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy

Michael Sun, Muhammad Niaz, Charlene Thomas, Ariel Schaap, Kristine Lacuna, Panagiotis Vlachostergios, Paul Christos, Ana M. Molina, David M. Nanus, Cora N. Sternberg, Joseph Osborne, Neil H. Bander, Scott T. Tagawa
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 6511.
https://doi.org/10.1158/1538-7445.AM2020-6511
Published: 15 August 2020
View articletitled, Abstract 6511: Androgen receptor (AR) genomic alterations and clinical outcome with prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy
Journal Articles

Abstract CT122: Phase I dose-escalation study of prostate-specific membrane antigen (PSMA)-targeted alpha emitter 225Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC)

Scott T. Tagawa, Joseph Osborne, Charlene Thomas, Escarleth Fernandez, Muhammad J. Niaz, Shankar Vallabhajosula, Panagiotis Vlachostergios, Ana M. Molina, Cora Sternberg, Sharon Singh, Amie Patel, Angela Tan, John Babich, David M. Nanus, Karla Ballman, Neil H. Bander
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): CT122.
https://doi.org/10.1158/1538-7445.AM2020-CT122
Published: 15 August 2020
View articletitled, Abstract CT122: Phase I dose-escalation study of prostate-specific membrane antigen (PSMA)-targeted alpha emitter 225Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC)
Journal Articles

Abstract 4865: Prognostic value of BRCA2 and AR gene alterations in advanced prostate cancer patients treated with PSMA-targeted radionuclide therapies

Panagiotis J. Vlachostergios, Vincenza Conteduca, Amy L. Hackett, Jyothi Manohar, Aileen Lee, Aidan Case, Michael Sun, Muhammad J. Niaz, Olivier Elemento, Ana M. Molina, David M. Nanus, Himisha Beltran, Neil H. Bander, Scott T. Tagawa
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 4865.
https://doi.org/10.1158/1538-7445.AM2019-4865
Published: 01 July 2019
View articletitled, Abstract 4865: Prognostic value of BRCA2 and AR gene alterations in advanced prostate cancer patients treated with PSMA-targeted radionuclide therapies
Journal Articles

Abstract 1774: External beam radiation therapy and androgen deprivation therapy increase PSMA expression in prostate cancer

Marigdalia K. Ramirez-Fort, Sean S. Mahase, M. Junaid Niaz, He Liu, Vincent Navarro, Goran Rac, Harry S. Clarke, Scott T. Tagawa, Joseph M. Jenrette, Neil H. Bander, Christopher S. Lange
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 1774.
https://doi.org/10.1158/1538-7445.AM2018-1774
Published: 01 July 2018
View articletitled, Abstract 1774: External beam radiation therapy and androgen deprivation therapy increase PSMA expression in prostate cancer
Journal Articles

Abstract 2518: Folate hydrolase-1 is a novel target for J591-brachytherapy in Merkel cell carcinoma

Barbara Meier, Marigdalia K. Ramirez-Fort, Kristina Lachance, Candice D. Church, Sean S. Mahase, Joseph M. Jenrette, Christopher S. Lange, Lars E. French, Paul Nghiem, Neil H. Bander
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 2518.
https://doi.org/10.1158/1538-7445.AM2018-2518
Published: 01 July 2018
View articletitled, Abstract 2518: Folate hydrolase-1 is a novel target for J591-brachytherapy in Merkel cell carcinoma
Journal Articles

Abstract 1905: Possible cancer stem cells: Folate hydrolase-1 is expressed in a subset of Oct4-positive melanoma cells

Marigdalia K. Ramirez-Fort, He Liu, Vicente Navarro, Barbara Meier, Mitch Levesque, Jonathan Moy, Jessica Vissicchio, Emmanuel Contassot, Sae Kim, Talal Syed, Michael Zhang, Vincent Tem, Paul J. Christos, Scott T. Tagawa, Neil H. Bander, Christopher S. Lange, Lars E. French
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 1905.
https://doi.org/10.1158/1538-7445.AM2017-1905
Published: 01 July 2017
View articletitled, Abstract 1905: Possible cancer stem cells: Folate hydrolase-1 is expressed in a subset of Oct4-positive melanoma cells
Journal Articles

Abstract 5201: PSMA-targeted alpha radioimmunotherapy for prostate cancer with 225Ac-J591

Jaspreet S. Batra, He Liu, Sae Kim, Vicente N. Navarro, Shankar Vallabhajosula, Scott T. Tagawa, Neil H. Bander
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 5201.
https://doi.org/10.1158/1538-7445.AM2017-5201
Published: 01 July 2017
View articletitled, Abstract 5201: PSMA-targeted alpha radioimmunotherapy for prostate cancer with 225Ac-J591
Journal Articles

Abstract 3971: Non-invasive assessment of prostate-specific membrane antigen (PSMA) expression as a prognostic marker in men with metastatic castration-resistant prostate cancer (mCRPC)

Kavya Pinto-Chengot, Yuliya Jhanwar, Jaspreet Batra, Beerinder Karir, Shankar Vallabhajosula, Paul Christos, Ana Molina, Himisha Beltran, David M. Nanus, Stanley J. Goldsmith, Neil H. Bander, Scott T. Tagawa
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 3971.
https://doi.org/10.1158/1538-7445.AM2016-3971
Published: 15 July 2016
View articletitled, Abstract 3971: Non-invasive assessment of prostate-specific membrane antigen (PSMA) expression as a prognostic marker in men with metastatic castration-resistant prostate cancer (mCRPC)
Journal Articles

Abstract CT140: Pilot study of “hyperfractionated” anti-prostate specific membrane antigen (PSMA) radioimmunotherapy (177Lu-J591) for progressive metastatic castration-resistant prostate cancer (mCRPC)

Ana M. Molina, Jaspreet S. Batra, Beerinder S. Karir, Yuliya Jhanwar, Shankar Vallabhajosula, Paul J. Christos, Linda Lam, Jennifer Epstein, Irene Karpenko, Himisha Beltran, David M. Nanus, Stanley J. Goldsmith, Neil H. Bander, Scott T. Tagawa
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): CT140.
https://doi.org/10.1158/1538-7445.AM2016-CT140
Published: 15 July 2016
View articletitled, Abstract CT140: Pilot study of “hyperfractionated” anti-prostate specific membrane antigen (PSMA) radioimmunotherapy (177Lu-J591) for progressive metastatic castration-resistant prostate cancer (mCRPC)
Journal Articles

Abstract CT306: Radiolabeled anti-PSMA antibody J591 immunotherapy is associated with favorable circulating tumor cell (CTC) count control in men with castration-resistant prostate cancer

Pravin Date, Beerinder S. Karir, Jaspreet S. Batra, Yuliya Jhanwar, Himisha Beltran, David M. Nanus, Neil H. Bander, Scott T. Tagawa
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): CT306.
https://doi.org/10.1158/1538-7445.AM2015-CT306
Published: 01 August 2015
View articletitled, Abstract CT306: Radiolabeled anti-PSMA antibody J591 immunotherapy is associated with favorable circulating tumor cell (CTC) count control in men with castration-resistant prostate cancer
Journal Articles

Abstract CT304: Anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 plus low-dose interleukin-2 (IL-2) in patients with recurrent prostate cancer (PC)

Yulian Khagi, Gurveen Kaur, Paul Christos, Naveed H. Akhtar, David M. Nanus, Neil H. Bander, Scott T. Tagawa
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): CT304.
https://doi.org/10.1158/1538-7445.AM2014-CT304
Published: 01 October 2014
View articletitled, Abstract CT304: Anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 plus low-dose interleukin-2 (IL-2) in patients with recurrent prostate cancer (PC)
Journal Articles

Abstract CT413: Lutetium-177-labeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (177Lu-J591) for metastatic non-prostate solid tumors

Orrin Pail, Gurveen Kaur, Jonathan Dyke, Yuliya Jhanwar, Paul Christos, Allyson Ocean, Manish Shah, Tsiporah Shore, Bryan Schneider, Ronald Scheff, Himisha Beltran, Douglas Ballon, Brian Robinson, David M. Nanus, Neil H. Bander, Scott T. Tagawa
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): CT413.
https://doi.org/10.1158/1538-7445.AM2014-CT413
Published: 01 October 2014
View articletitled, Abstract CT413: Lutetium-177-labeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (177Lu-J591) for metastatic non-prostate solid tumors
Journal Articles

Abstract 4696: Non-invasive measurement of prostate-specific membrane antigen (PSMA) expression with radiolabeled J591 imaging: a promising biomarker for PSMA-based radioimmunotherapy.

Naveed H. Akhtar, Joseph Osborne, David M. Nanus, Shankar Vallabhajosula, Stanley J. Goldsmith, Neil H. Bander, Scott T. Tagawa
Journal: Cancer Research
Cancer Res (2013) 73 (8_Supplement): 4696.
https://doi.org/10.1158/1538-7445.AM2013-4696
Published: 15 April 2013
View articletitled, Abstract 4696: Non-invasive measurement of prostate-specific membrane antigen (PSMA) expression with radiolabeled J591 imaging: a promising biomarker for PSMA-based radioimmunotherapy.
Journal Articles

Abstract 748: Phase I trial of fractionated-dose 177Lutetium radiolabeled anti-prostate-specific membrane antigen monoclonal antibody J591 (177Lu-J591) in patients with metastatic castration-resistant prostate cancer (metCRPC)

Scott T. Tagawa, Shankar Vallabhajosula, Naveed H. Akhtar, Joseph Osborne, Himisha Beltran, Ankeeta Saran, Gina Mileo, Caryn Ecker, Stanley J. Goldsmith, David M. Nanus, Neil H. Bander
Journal: Cancer Research
Cancer Res (2012) 72 (8_Supplement): 748.
https://doi.org/10.1158/1538-7445.AM2012-748
Published: 15 April 2012
View articletitled, Abstract 748: Phase I trial of fractionated-dose 177Lutetium radiolabeled anti-prostate-specific membrane antigen monoclonal antibody J591 (177Lu-J591) in patients with metastatic castration-resistant prostate cancer (metCRPC)
Journal Articles

Taxane-Induced Blockade to Nuclear Accumulation of the Androgen Receptor Predicts Clinical Responses in Metastatic Prostate Cancer

Medha S. Darshan, Matthew S. Loftus, Maria Thadani-Mulero, Benjamin P. Levy, Daniel Escuin, Xi Kathy Zhou, Ada Gjyrezi, Chantal Chanel-Vos, Ruoqian Shen, Scott T. Tagawa, Neil H. Bander, David M. Nanus, Paraskevi Giannakakou
Journal: Cancer Research
Cancer Res (2011) 71 (18): 6019–6029.
https://doi.org/10.1158/0008-5472.CAN-11-1417
Published: 13 September 2011
View articletitled, Taxane-Induced Blockade to Nuclear Accumulation of the Androgen Receptor Predicts Clinical Responses in Metastatic Prostate Cancer
Open the PDF for Taxane-Induced Blockade to Nuclear Accumulation of the Androgen Receptor Predicts Clinical Responses in Metastatic Prostate Cancer in another window
Includes: Multimedia, Supplementary data
Journal Articles

A functional role of prostate-specific membrane antigen in prostate cancer metastasis

Sharron X. Lin, Vincent Navarro, He Liu, Neil H. Bander
Journal: Cancer Research
Cancer Res (2006) 66 (8_Supplement): 1027.
Published: 15 April 2006
View articletitled, A functional role of prostate-specific membrane antigen in prostate cancer metastasis